Format

Send to:

Choose Destination
See comment in PubMed Commons below
Yale J Biol Med. 2010 Jun;83(2):53-65.

Role and cost effectiveness of PET/CT in management of patients with cancer.

Author information

  • 1Yale University School of Medicine, Section of Medical Oncology, New Haven, Connecticut 06520, USA. wasif.saif@yale.edu

Abstract

PET/CT is a relatively new imaging technology, whose undoubted advantages are valuable in clinical oncology as well as in all fields of diagnosis, staging, and treatment. The hardware combination of anatomy and function has been the true evolution in imaging. PET using 18F-fluorodeoxyglucose (FDG) is increasingly used for the staging of solid malignancies, including colon, lung, etc., but anatomic information is limited. Integrated PET/CT enables optimal anatomic delineation of PET findings and identification of FDG-negative lesions on computed tomography (CT) images and might improve preoperative staging. However, controversy still exists in relation to the application of PET/CT in clinical practice, mainly because of its high cost. It is evident that apart from additional costs, potential savings also are associated with PET/CT as a result of avoiding additional imaging examinations or invasive procedures and by helping clinicians make the optimum treatment decisions. The authors review the literature on the role of PET/CT in management of various tumors and discuss the medicoeconomic usefulness.

KEYWORDS:

18F-fluorodeoxyglucose (FDG); CT; PET; cancer; diagnosis; imaging

PMID:
20589185
[PubMed - indexed for MEDLINE]
PMCID:
PMC2892773
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk